Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940, Including an Interaction Study, After Administration of Oral Multiple Ascending Doses in Adult Subjects With Chronic Low Back Pain.

Next Previous
Trial Profile

A Phase I, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940, Including an Interaction Study, After Administration of Oral Multiple Ascending Doses in Adult Subjects With Chronic Low Back Pain.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NEO 1940 (Primary) ; Midazolam
  • Indications Back pain
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AstraZeneca

Most Recent Events

  • 09 Dec 2010 Actual end date changed from Jan 2009 to Nov 2008 as reported by ClinicalTrials.gov.
  • 23 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 24 Jun 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top